Cord Blood vs Cord Tissue vs Placental Tissue: What's the Difference?
Private banks increasingly sell three things at once: cord blood, cord tissue, and sometimes placental tissue. They sound similar but contain meaningfully different stem cells with very different evidence behind them.
Cord blood
Cord blood contains hematopoietic stem cells (HSCs) — the cells that build the blood and immune system. These have an established, FDA-approved role in treating roughly 80 conditions, mostly blood cancers, inherited blood disorders, and certain immune deficiencies. This is the most clinically validated of the three.
Cord tissue
Cord tissue contains mesenchymal stem cells (MSCs), which can develop into bone, cartilage, fat, and other connective tissues. As of 2025, there are no FDA-approved standard therapies using autologous cord tissue MSCs — they're an active area of clinical research for conditions like osteoarthritis, autoimmune disease, and orthopedic injuries. Banking is reasonable for future-research optionality, but should not be framed as proven medicine.
Placental tissue
Placental tissue is the newest addition and contains a mix of stem cell types, including additional MSCs and epithelial stem cells. Like cord tissue, placental tissue banking is largely a bet on future regenerative medicine research. Evidence here is even more preliminary than cord tissue, and many transplant physicians consider it experimental.
Honest comparison
- Cord blood: proven, FDA-approved, ~80 indications — the clinical workhorse
- Cord tissue: research-stage MSCs with promising but unproven applications
- Placental tissue: experimental; weakest evidence of the three
- Bundled pricing makes adding tissues cheap up front, but storage fees compound over decades